VRTX Stock News & Catalysts – Vertex Pharmaceuticals

FEATURED

Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment

New

NEW YORK, Nov. 9, 2026 /CNW/ -- Market Updates News Commentary - Health care stocks moved higher with the broader market on Monday morning. As of 9:58 a.m. ET, the State Street Health Care Select Sector SPDR ETF was up

Summary

Nov 9, 2026, 11:36 AM ·PRNewswire

RECENT

Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story

NEW YORK, Nov. 4, 2026 /CNW/ -- Fly on Wall Street News Commentary - Wall Street's major indexes rallied together on Wednesday. As of 2:31 p.m. ET, the Dow Jones Industrial Average was up 1,552.12 points, or 3.0%,

Nov 4, 2026, 4:06 PM ·PRNewswire

Vertex to Participate in Upcoming Investor Conferences

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive

Nov 4, 2026, 4:00 PM ·Business Wire

Vertex Reports Third Quarter 2026 Financial Results

— Achieved total revenue of $3.44 billion, a 12% increase compared to third quarter 2025 — — Raising full-year revenue guidance to $13.15 billion to $13.25 billion — — Established fourth commercial pillar in rare

Nov 2, 2026, 4:01 PM ·Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept – - Data published in NEJM and presented at ASN highlight

Oct 23, 2026, 1:42 PM ·Business Wire

Vertex Appoints Daniel Brennan to its Board of Directors

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director. Mr. Brennan has more than 35 years of experience in finance

Oct 20, 2026, 4:05 PM ·Business Wire

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children – - Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex

Oct 9, 2026, 1:15 PM ·Business Wire

Vertex to Announce Third Quarter 2026 Financial Results November 2nd

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast

Oct 7, 2026, 4:00 PM ·Business Wire

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

– In people with AMKD with modest proteinuria, treatment with inaxaplin led to a reduction in urine albumin to creatinine ratio (UACR) of -42.7% at Week 13 compared to baseline – - In people with AMKD and type 2

Sep 22, 2026, 8:00 AM ·Business Wire

Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain

- Vonn shares her experience using JOURNAVX to manage her acute pain after a career-altering injury at the 2026 Winter Games - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the company has

Sep 15, 2026, 7:30 AM ·Business Wire

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

Issued on behalf of AVAI Bio, Inc. LAS VEGAS, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - Type 1 diabetes has an unusual property among serious diseases: the science of curing it is largely

Sep 8, 2026, 9:00 AM ·Globe Newswire

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Crinetics acquisition completed September 1, 2026 Charles Wagner, EVP, Chief Operating and Financial Officer to take on expanded COO role overseeing integration of Crinetics, effective immediately As part of a

Sep 1, 2026, 9:03 AM ·Business Wire

Vertex to Participate in Upcoming September Investor Conferences

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive

Aug 26, 2026, 4:00 PM ·Business Wire

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to

Aug 17, 2026, 12:57 PM ·Business Wire

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product

Aug 3, 2026, 4:05 PM ·Globe Newswire

Vertex Pharmaceuticals Incorporated VRTX · News